GENFIT Announces Strong 2023 Financials and Progress
Company Announcements

GENFIT Announces Strong 2023 Financials and Progress

Genfit (GNFT) has released an update.

GENFIT, a biopharmaceutical company focusing on liver diseases, reported a solid financial position with €77.8 million in cash and €28.6 million in revenue for the year 2023, boosted by a milestone payment of €13.3 million. The company highlighted significant progress in its drug development, including positive Phase 3 trial results for elafibranor in PBC and the advancement of its acute-on-chronic liver failure (ACLF) program with multiple assets. GENFIT anticipates key regulatory dates and trial data in 2024, aiming to address unmet medical needs in liver disease treatment.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit’s Iqirvo Wins EU Approval for Liver Condition
TipRanks Auto-Generated NewsdeskGENFIT SA Showcases Robust 2024 Financial Health
TipRanks Auto-Generated NewsdeskGenfit SA Expands R&D, Gains FDA Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App